Paper39355199
Investigating the Correlation Between Long-Term Response in Patients with Metastatic HER2+ Breast Cancer and the Activity of Regulatory T Cells: A Retrospective Study.
Degirmenci M and 6 others. Breast Cancer (Dove Med Press), 2024. Cited by 1 paper, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Investigating the Correlation Between Long-Term Response in Patients with Metastatic HER2+ Breast Cancer and the Activity of Regulatory T Cells: A Retrospective Study. Papers, record 39355199. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39355199
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Investigating the Correlation Between Long-Term Response in Patients with Metastatic HER2+ Breast Cancer and the Activity of Regulatory T Cells: A Retrospective Study.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References42
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 20027191 | Molecular predictors of response to trastuzumab and lapatinib in breast cancer. | Nat Rev Clin Oncol | 2010 | https://conductscience.org/library/papers/20027191 | PubMed |
| 2 | 15809519 | A retrospective series of long-term survivors of metastatic breast cancer in complete remission. | Oncology | 2005 | https://conductscience.org/library/papers/15809519 | PubMed |
| 3 | 22172323 | PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab. | Ann Oncol | 2012 | https://conductscience.org/library/papers/22172323 | PubMed |
| 4 | 22767587 | Durable complete response following chemotherapy and trastuzumab for metastatic HER2-positive breast cancer. | Ann Oncol | 2012 | https://conductscience.org/library/papers/22767587 | PubMed |
| 5 | 27777963 | Crucial Contributions by T Lymphocytes (Effector, Regulatory, and Checkpoint Inhibitor) and Cytokines (TH1, TH2, and TH17) to a Pathological Complete Response Induced by Neoadjuvant Chemotherapy in Women with Breast Cancer. | J Immunol Res | 2016 | https://conductscience.org/library/papers/27777963 | PubMed |
| 6 | 11251000 | Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial. | J Clin Oncol | 2001 | https://conductscience.org/library/papers/11251000 | PubMed |
| 7 | 11248153 | Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. | N Engl J Med | 2001 | https://conductscience.org/library/papers/11248153 | PubMed |
| 8 | 8708708 | Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. | J Clin Oncol | 1996 | https://conductscience.org/library/papers/8708708 | PubMed |
| 9 | 8943669 | Characterisation of complete responders to combination chemotherapy for advanced breast cancer: a retrospective EORTC Breast Group study. | Eur J Cancer | 1996 | https://conductscience.org/library/papers/8943669 | PubMed |
| 10 | 23908178 | Human epidermal growth factor receptor 2 (HER2)-positive and hormone receptor-positive breast cancer: new insights into molecular interactions and clinical implications. | Ann Oncol | 2013 | https://conductscience.org/library/papers/23908178 | PubMed |
| 11 | 27143924 | Clinicopathological characteristics of patients with HER2-positive breast cancer and the efficacy of trastuzumab in the People's Republic of China. | Onco Targets Ther | 2016 | https://conductscience.org/library/papers/27143924 | PubMed |
| 12 | 18038883 | When should trastuzumab be stopped after achieving complete response in HER2-positive metastatic breast cancer patients? | Tumori | 2007 | https://conductscience.org/library/papers/18038883 | PubMed |
| 13 | 35804943 | Immunological Landscape of HER-2 Positive Breast Cancer. | Cancers (Basel) | 2022 | https://conductscience.org/library/papers/35804943 | PubMed |
| 14 | 32222891 | Prognostic impact of a tumor-infiltrating lymphocyte subtype in triple negative cancer of the breast. | Breast Cancer | 2020 | https://conductscience.org/library/papers/32222891 | PubMed |
| 15 | 34339645 | Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials. | Lancet Oncol | 2021 | https://conductscience.org/library/papers/34339645 | PubMed |
| 16 | 16683005 | Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. | Nat Clin Pract Oncol | 2006 | https://conductscience.org/library/papers/16683005 | PubMed |
| 17 | 21115860 | Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens. | J Clin Oncol | 2011 | https://conductscience.org/library/papers/21115860 | PubMed |
| 18 | 37783133 | Evolving treatments and outcomes in HER2-Positive metastatic breast cancer: Data from the GIM14/BIOMETA study. | Breast | 2023 | https://conductscience.org/library/papers/37783133 | PubMed |
| 19 | 20210247 | Inhibition of HER2/estrogen receptor cross-talk, probable relation to prolonged remission of stage IV breast cancer: a case report. | Tumori | 2009 | https://conductscience.org/library/papers/20210247 | PubMed |
| 20 | 26648738 | Hormone receptor status predicts the clinical outcome of human epidermal growth factor 2-positive metastatic breast cancer patients receiving trastuzumab therapy: a multicenter retrospective study. | Onco Targets Ther | 2015 | https://conductscience.org/library/papers/26648738 | PubMed |
Cited by1
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1 citation.
| PMID | Title | Journal | Year | In Papers |
|---|---|---|---|---|
| 40437918 | Evaluation of Tissue Expression of HMBG1 Protein in Patients With Breast Cancer. | Eur J Breast Health | 2025 | https://conductscience.org/library/papers/40437918 |
Source PubMed
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| ERBB2 | 2064 | PubTator's text mining | https://conductscience.org/library/genes/2064 | NCBI Gene |
| FOXP3 | 50943 | PubTator's text mining | https://conductscience.org/library/genes/50943 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39355199
GET https://conductscience.org/api/papers/v1/39355199/references?page=2